Guanine nucleotide binding to the Bateman domain mediates the allosteric inhibition of eukaryotic IMP dehydrogenases

Nature Communications

Volumn 6, Issue , 2015, Pages

  Buey, Rubén M ^a   Ledesma Amaro, Rodrigo ^a   Velázquez Campoy, Adrián ^b,c,d   Balsera, Mónica ^e   Chagoyen, Mónica ^f   De Pereda, José M ^g   Revuelta, José L ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^d FUNDACIÓN ARAID   (Spain)

^e INSTITUTO DE RECURSOS NATURALES Y AGROBIOLOGÍA DE SALAMANCA   (Spain)

^f CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^g Salamanca Spain   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BATEMAN PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; UNCLASSIFIED DRUG; PROTEIN BINDING;

AMINO ACID; CATALYSIS; ENZYME ACTIVITY; EUKARYOTE; FUNGUS; INHIBITION; METABOLISM; PROKARYOTE;

ALLOSTERISM; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EREMOTHECIUM GOSSYPII; EUKARYOTE; FUNGUS MUTATION; HUMAN; NONHUMAN; NUCLEOTIDE BINDING SITE; PROTEIN BINDING; PROTEIN DOMAIN; RETINOPATHY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; ASCOMYCETES; ENZYMOLOGY; METABOLISM; MOLECULAR GENETICS; MOLECULAR MODEL; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE;

EREMOTHECIUM GOSSYPII; EUKARYOTA; PROKARYOTA;

AMINO ACID SEQUENCE; ASCOMYCOTA; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; IMP DEHYDROGENASE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY;

EID: 84947051646     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9923     Document Type: Article

References (57)

1. Chong, C. R. et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J. Med. Chem. 49, 2677-2680 (2006).
2. Long, H., Cameron, S., Yu, L. & Rao, Y. De novo GMP synthesis is required for axon guidance in Drosophila. Genetics 172, 1633-1642 (2006).
3. Jayaram, H. N., Cooney, D. A., Grusch, M. & Krupitza, G. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Curr. Med. Chem. 6, 561-574 (1999).
4. Allison, A. C. & Eugui, E. M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47, 85-118 (2000).
5. Braun-Sand, S. B. & Peetz, M. Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics. Future Med. Chem. 2, 81-92 (2010).
6. Buey, R. M., Ledesma-Amaro, R., Balsera, M., de Pereda, J. M. & Revuelta, J. L. Increased riboflavin production by manipulation of inosine 5′-monophosphate dehydrogenase in Ashbya gossypii. Appl. Microbiol. Biotechnol. doi:10.1007/s00253-00015-06710-00252 (2015).
7. Nagano, N., Orengo, C. A. & Thornton, J. M. One fold with many functions: the evolutionary relationships between TIM barrel families based on their sequences, structures and functions. J. Mol. Biol. 321, 741-765 (2002).
8. Bateman, A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem. Sci. 22, 12-13 (1997).
9. Scott, J. et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J. Clin. Invest. 113, 274-284 (2004).
10. Ignoul, S. & Eggermont, J. CBS domains: structure, function, and pathology in human proteins. Am. J. Physiol. Cell Physiol. 289, C1369-C1378 (2005).
11. Baykov, A. A., Tuominen, H. K. & Lahti, R. The CBS domain: a protein module with an emerging prominent role in regulation. ACS Chem. Biol. 6, 1156-1163 (2011).
12. Ereno-Orbea, J., Oyenarte, I. & Martinez-Cruz, L. A. CBS domains: ligand binding sites and conformational variability. Arch. Biochem. Biophys. 540, 70-81 (2013).
13. McGrew, D. A. & Hedstrom, L. Towards a pathological mechanism for IMPDH1-linked retinitis pigmentosa. Adv. Exp. Med. Biol. 723, 539-545 (2012).
14. Nimmesgern, E. et al. Biochemical analysis of the modular enzyme inosine 5′-monophosphate dehydrogenase. Protein Expr. Purif. 17, 282-289 (1999).
15. Pimkin, M. & Markham, G. The CBS subdomain of inosine 5′-monophosphate dehydrogenase regulates purine nucleotide turnover. Mol. Microbiol. 68, 342-359 (2008).
16. Labesse, G. et al. MgATP regulates allostery and fiber formation in IMPDHs. Structure 21, 975-985 (2013).
17. Mortimer, S. & Hedstrom, L. Autosomal dominant retinitis pigmentosa mutations in inosine 5′-monophosphate dehydrogenase type I disrupt nucleic acid binding. Biochem. J. 390, 41-47 (2005).
18. Kozhevnikova, E. N. et al. Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. Mol. Cell 47, 133-139 (2012).
19. Ji, Y., Gu, J., Makhov, A., Griffith, J. & Mitchell, B. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J. Biol. Chem. 281, 206-212 (2006).
20. Thomas, E. et al. Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms. PLoS ONE 7, e51096 (2012).
21. Ledesma-Amaro, R., Buey, R. M. & Revuelta, J. L. Increased production of inosine and guanosine by means of metabolic engineering of the purine pathway in Ashbya gossypii. Microb. Cell Fact. 14, 58 (2015).
22. Zhang, R. et al. Differential signatures of bacterial and mammalian IMP dehydrogenase enzymes. Curr. Med. Chem. 6, 537-543 (1999).
23. Makowska-Grzyska, M. et al. Bacillus anthracis inosine 5′-monophosphate dehydrogenase in action: the first bacterial series of structures of phosphate ion-, substrate-, and product-bound complexes. Biochemistry 51, 6148-6163 (2012).
24. Zhang, R. et al. Characteristics and crystal structure of bacterial inosine-5′-monophosphate dehydrogenase. Biochemistry 38, 4691-4700 (1999).
25. Wada, Y. et al. Screening for mutations in the IMPDH1 gene in Japanese patients with autosomal dominant retinitis pigmentosa. Am. J. Ophthalmol. 140, 163-165 (2005).
26. Gomez-Garcia, I., Oyenarte, I. & Martinez-Cruz, L. A. The crystal structure of protein MJ1225 from Methanocaldococcus jannaschii shows strong conservation of key structural features seen in the eukaryal gamma-AMPK. J. Mol. Biol. 399, 53-70 (2010).
27. Alexandre, T., Rayna, B. & Munier-Lehmann, H. Two classes of bacterial IMPDHs according to their quaternary structures and catalytic properties. PLoS ONE 10, e0116578 (2015).
28. del Sol, A., Pazos, F. & Valencia, A. Automatic methods for predicting functionally important residues. J. Mol. Biol. 326, 1289-1302 (2003).
29. Traut, T. W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140, 1-22 (1994).
30. Makowska-Grzyska, M. et al. A novel cofactor-binding mode in bacterial IMP dehydrogenases explains inhibitor selectivity. J. Biol. Chem. 290, 5893-5911 (2015).
31. Wada, Y. et al. Screen of the IMPDH1 gene among patients with dominant retinitis pigmentosa and clinical features associated with the most common mutation, Asp226Asn. Invest. Ophthalmol. Vis. Sci. 46, 1735-1741 (2005).
32. Kennan, A. et al. Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum. Mol. Genet. 11, 547-557 (2002).
33. Bowne, S. J. et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 11, 559-568 (2002).
34. Aherne, A. et al. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa. Hum. Mol. Genet. 13, 641-650 (2004).
35. La Cour, M. Adler's Physiology of the Eye. 10th edn, 348-357 (2002).
36. Ledesma-Amaro, R., Santos, M. A., Jimenez, A. & Revuelta, J. L. Strain design of Ashbya gossypii for single-cell oil production. Appl. Environ. Microbiol. 80, 1237-1244 (2014).
37. Ledesma-Amaro, R., Santos, M. A., Jimenez, A. & Revuelta, J. L. Tuning single-cell oil production in Ashbya gossypii by engineering the elongation and desaturation systems. Biotechnol. Bioeng. 111, 1782-1791 (2014).
38. Forster, C., Santos, M. A., Ruffert, S., Kramer, R. & Revuelta, J. L. Physiological consequence of disruption of the VMA1 gene in the riboflavin overproducer Ashbya gossypii. J. Biol. Chem. 274, 9442-9448 (1999).
39. Jimenez, A., Santos, M. A., Pompejus, M. & Revuelta, J. L. Metabolic engineering of the purine pathway for riboflavin production in Ashbya gossypii. Appl. Environ. Microbiol. 71, 5743-5751 (2005).
40. Jimenez, A., Santos, M. A. & Revuelta, J. L. Phosphoribosyl pyrophosphate synthetase activity affects growth and riboflavin production in Ashbya gossypii. BMC Biotechnol. 8, 67 (2008).
41. Alonso-Garcia, N., Ingles-Prieto, A., Sonnenberg, A. & de Pereda, J. M. Structure of the Calx-beta domain of the integrin beta4 subunit: insights into function and cation-independent stability. Acta Crystallogr. D Biol. Crystallogr. 65, 858-871 (2009).
42. Guinier, A. & Fournet, F. Small Angle Scattering of X-rays (Wiley Interscience, 1955).
43. Svergun, D. I. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Crystallogr. 25, 495-503 (1992).
44. Svergun, D. I., Barberato, C. & Koch, M. H. J. Crysol- a program to evaluate x-ray solution scattering of biological macromolecules from atomic coordinates. J. Appl. Crystallogr. 28, 768-773 (1995).
45. Juanhuix, J. et al. Developments in optics and performance at BL13-XALOC, the macromolecular crystallography beamline at the ALBA synchrotron. J. Synchrotron Radiat 21, 679-689 (2014).
46. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
47. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
48. Potterton, E., Briggs, P., Turkenburg, M. & Dodson, E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. D Biol. Crystallogr. 59, 1131-1137 (2003).
49. Moynie, L. et al. The AEROPATH project targeting Pseudomonas aeruginosa: crystallographic studies for assessment of potential targets in early-stage drug discovery. Acta Crystallogr. F Struct. Biol. Crystal. Commun. 69, 25-34 (2013).
50. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
51. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
52. Winn, M. D., Isupov, M. N. & Murshudov, G. N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 57, 122-133 (2001).
53. Biasini, M. et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 42, W252-W258 (2014).
54. Eddy, S. R. Accelerated profile HMM searches. PLoS Comput. Biol. 7, e1002195 (2011).
55. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792-1797 (2004).
56. Rausell, A., Juan, D., Pazos, F. & Valencia, A. Protein interactions and ligand binding: from protein subfamilies to functional specificity. Proc. Natl Acad. Sci. USA 107, 1995-2000 (2010).
57. Muth, T. et al. JDet: interactive calculation and visualization of function-related conservation patterns in multiple sequence alignments and structures. Bioinformatics 28, 584-586 (2012).